Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHRQ plans effectiveness review of tests for breast abnormalities

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research and Quality posts for review three key questions on the comparative effectiveness of noninvasive diagnostic tests for breast abnormalities. The review will evaluate ultrasound, magnetic resonance imaging, positron emission tomography and scintimammography for the diagnosis of breast cancer in women referred for tests after a possible breast abnormality is found during routine screening. AHRQ will address key demographic risk factors and clinical risk factors, as well as other potential risk factors that could impact test accuracy. Comments on the draft questions are due May 5

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel